Found: 18
Select item for more details and to access through your institution.
Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.
- Published in:
- Medical Mycology, 2011, v. 49, n. 7, p. 681, doi. 10.3109/13693786.2011.557668
- By:
- Publication type:
- Article
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 337, doi. 10.1111/bjh.16083
- By:
- Publication type:
- Article
BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1632, doi. 10.1002/ajh.27359
- By:
- Publication type:
- Article
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. E296, doi. 10.1002/ajh.26618
- By:
- Publication type:
- Article
High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0051527
- By:
- Publication type:
- Article
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4161, doi. 10.3390/cancers15164161
- By:
- Publication type:
- Article
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.
- Published in:
- Cancers, 2019, v. 11, n. 4, p. 570, doi. 10.3390/cancers11040570
- By:
- Publication type:
- Article
Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 16, p. 16929, doi. 10.1002/cam4.6322
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Long-Term Follow-Up of De Novo Chronic Phase Chronic Myelogenous Leukemia Patients on Imatinib First-Line.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S306, doi. 10.1016/j.clml.2017.07.103
- By:
- Publication type:
- Article
A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome.
- Published in:
- Cell Death & Disease, 2018, v. 9, n. 10, p. 1, doi. 10.1038/s41419-018-1042-7
- By:
- Publication type:
- Article
ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 1, p. 37, doi. 10.1002/ajh.23864
- By:
- Publication type:
- Article
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 24, p. 4284, doi. 10.1002/cncr.28328
- By:
- Publication type:
- Article
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 1, p. 107, doi. 10.1002/cncr.27686
- By:
- Publication type:
- Article
Reduction of Invasive Aspergillosis Incidence among Immunocompromised Patients after Control of Environmental Exposure.
- Published in:
- Clinical Infectious Diseases, 2007, v. 45, n. 6, p. 682, doi. 10.1086/521378
- By:
- Publication type:
- Article